SCHEMBL3776982

SCHEMBL3776982

Cc1c(Cc2ccc(F)cc2Cl)c(=O)[nH]c2c(F)ccc(O)c12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
HTT P42858 2/20 0.38
ALDH1A1 P00352 2/20 0.38
LMNA P02545 1/20 0.38
HPGD P15428 1/20 0.38
HSD17B10 Q99714 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.37
P2RX7 Q99572 8/20 0.36
KCNH2 Q12809 1/20 0.36
POLB P06746 3/20 0.35
DUSP3 P51452 1/20 0.35
PTPN5 P54829 1/20 0.35
PTPN11 Q06124 1/20 0.35
CTDSP1 Q9GZU7 1/20 0.35
SAE1 Q9UBE0 1/20 0.35
UBA2 Q9UBT2 1/20 0.35
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
PKM P14618 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3785180 0.92 KDM4E (0.47) KDM4EL3MBTL1HTTALDH1A1LMNA
SCHEMBL3782767 0.90 PTGS1 (0.41) KDM4EP2RX7KCNH2NEK1
SCHEMBL3784913 0.86 PTGS2 (0.41) KDM4EL3MBTL1HTTALDH1A1HPGD
SCHEMBL3779905 0.86 KDM4E (0.38) KDM4EL3MBTL1HTTALDH1A1LMNA
SCHEMBL3778310 0.81 ALDH1A1 (0.39) ALDH1A1LMNASMN1; SMN2POLBMAPT
SCHEMBL3781883 0.80 ALDH1A1 (0.40) KDM4EL3MBTL1HTTALDH1A1LMNA
SCHEMBL3344884 0.80 SLC2A1 (0.39) HTTALDH1A1LMNAMEN1KMT2A
SCHEMBL3788176 0.76 PTGS2 (0.43) KDM4EL3MBTL1ALDH1A1LMNASMN1; SMN2
SCHEMBL2573266 0.74 PDE3B (0.37) KDM4EALDH1A1LMNAHPGDNEK1
SCHEMBL3773003 0.73 KDM4E (0.40) KDM4EL3MBTL1HTTALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1928457-B1 QUINOLINES AND THEIR THERAPEUTIC USE PULMAGEN THERAPEUTICS ASTHMA LTD (GB) 2012-12-12 EP disclosed
US-7858640-B2 Quinolines and their therapeutic use PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) 2010-12-28 US disclosed
US-20090156600-A1 Quinolines and Their Therapeutic Use GB005, INC. 2009-06-18 US disclosed
EP-1928457-A2 QUINOLINES AND THEIR THERAPEUTIC USE Argenta Discovery Limited (GB) 2008-06-11 EP disclosed
WO-2007036743-A2 QUINOLINES AND THEIR THERAPEUTIC USE ARGENTA DISCOVERY LIMITED (GB) 2007-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156600-A1 Quinolines and Their Therapeutic Use NR3C1, NR3C2, NR1H3 KDM4E 4638/4885L3MBTL1 3442/4885HTT 3597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.